Compare Logitech International SA (LOGI) vs Novavax Inc (NVAX) Price & Performance

Logitech (LOGI) trades at $104.87, down 1.37% on the day, with a neutral technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat estimates with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand, though a key supplier shutdown clouds near-term outlook. Fundamentals show strong profitability with a 16.28% net margin and 35.29% ROE, while valuation metrics like a P/E of 19.03 appear reasonable. The stock faces resistance near $109, with support at $104.

The outlook is cautiously optimistic given solid earnings momentum and margin expansion, but supply chain disruptions pose a near-term risk. Upside to the $109.75 consensus price target offers potential, though investor sentiment is divided amid operational uncertainties. Key risks include supplier dependency and competitive pressures in the tech peripherals market.

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.